Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Patients with Neovascular Age-Related Macular Degeneration and Poor Visual Acuity

Abstract

To investigate the significance of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD) and poor visual acuity (VA). Retrospective study of patients with nAMD with baseline best corrected VA of ≤ 20/200. Patients were divided into regular treatment (RT) and scarce treatment (ST) groups according to whether they underwent consecutive intravitreal anti-VEGF treatments at intervals of ≤ 4 months or not. A total of 131 eyes were included: 87 and 44 eyes in the RT and ST groups, respectively. RT group showed significantly improved preservation of lesion size at both years 1 and 2, with significantly fewer incidences of new subretinal hemorrhage (SRH). Improvements in VA, reduction in central subfield macular thickness (CST), and maximal height of choroidal neovascularization were significantly favorable in RT group at year 1, and CST was significantly decreased at year 2. Survival analysis revealed that RT group had significantly greater preservation of VA and lesion size than that in ST group. Maintaining intravitreal anti-VEGF treatment for patients with nAMD and poor vision showed significant advantages in VA and lesion size stability and reduced the incidence of new SRH, which suggests preservation of paracentral vision.